Patents by Inventor Martine Petronella Bos

Martine Petronella Bos has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • VACCINE COMPRISING PROTEIN NMB0964 FROM NEISSERIA MENINGITIDIS
    Publication number: 20160243211
    Abstract: The present invention relates to immunogenic compositions comprising neisserial blebs with upregulated levels of the NMB0964 antigens such that bactericidal antibodies are generated against said antigen. It has been found for the first time that this antigen's expression is zinc regulated and therefore methods are provided to upregulated expression through removal of the zinc repression mechanism of the cell or promoter, or through removal of zinc from the culture medium.
    Type: Application
    Filed: January 7, 2016
    Publication date: August 25, 2016
    Inventors: Martine Petronella Bos, Jan Poolman, Michiel Stork, Johannes Petrus Maria Tommassen, Vincent Weynants
  • Vaccine comprising protein NMB0964 from
    Patent number: 9259461
    Abstract: The present invention relates to immunogenic compositions comprising neisserial blebs with upregulated levels of the NMB0964 antigens such that bacterial antibodies are generated against said antigen. Methods are also provided to upregulate expression through removal of the zinc repression mechanism of the cell or promoter or through removal of zinc from the culture medium.
    Type: Grant
    Filed: March 6, 2009
    Date of Patent: February 16, 2016
    Assignee: GlaxoSmithKline Biologicals, S.A.
    Inventors: Martine Petronella Bos, Jan Poolman, Michiel Stork, Johannes Petrus Maria Tommassen, Vincent Weynants
  • Outer membrane vesicles and uses thereof
    Patent number: 8163295
    Abstract: The present invention discloses a Gram negative bacterium in which the expression of a protein involved in LPS transport to the outer membrane is functionally down-regulated such that the level of LPS in the outer membrane is decreased compared to a wild-type Gram negative bacterium. Down regulation of Imp and MsbA proteins can result in such a bacterium. Outer membrane vesicle preparations derived from the Gram negative bacterium of the invention can be used in vaccines to provide protection against bacterial infection.
    Type: Grant
    Filed: August 17, 2011
    Date of Patent: April 24, 2012
    Assignees: GlaxoSmithKline Biologicals S.A., University of Utrecht
    Inventors: Martine Petronella Bos, Jan Poolman, Boris Tefson, Johannes Petrus Maria Tommassen
  • OUTER MEMBRANE VESICLES AND USES THEREOF
    Publication number: 20120039942
    Abstract: The present invention discloses a Gram negative bacterium in which the expression of a protein involved in LPS transport to the outer membrane is functionally down-regulated such that the level of LPS in the outer membrane is decreased compared to a wild-type Gram negative bacterium. Down regulation of Imp and MsbA proteins can result in such a bacterium. Outer membrane vesicle preparations derived from the Gram negative bacterium of the invention can be used in vaccines to provide protection against bacterial infection.
    Type: Application
    Filed: August 17, 2011
    Publication date: February 16, 2012
    Applicants: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventors: Martine Petronella Bos, Jan Poolman, Boris Tefson, Johannes Petrus Maria Tommassen
  • Outer membrane vesicles and uses thereof
    Patent number: 8029807
    Abstract: The present invention discloses a Gram negative bacterium in which the expression of a protein involved in LPS transport to the outer membrane is functionally downregulated such that the level of LPS in the outer membrane is decreased compared to a wild-type Gram negative bacterium. Down regulation of Imp and MsbA proteins can result in such a bacterium. Outer membrane vesicle preparations derived from the Gram negative bacterium of the invention can be used in vaccines to provide protection against bacterial infection.
    Type: Grant
    Filed: November 3, 2009
    Date of Patent: October 4, 2011
    Assignees: GlaxoSmithKline Biologicals S.A., University of Utrecht
    Inventors: Martine Petronella Bos, Jan Poolman, Boris Tefson, Johannes Petrus Maria Tommassen
  • Vaccine Comprising Protein NMB0964 From Neisseria Meningitidis
    Publication number: 20110189215
    Abstract: The present invention relates to immunogenic compositions comprising neisserial blebs with upregulated levels of the NMB0964 antigens such that bacterial antibodies are generated against said antigen. Methods are also provided to upregulate expression through removal of the zinc repression mechanism of the cell or promoter or through removal of zinc from the culture medium.
    Type: Application
    Filed: March 6, 2009
    Publication date: August 4, 2011
    Inventors: Martine Petronella Bos, Jan Poolman, Michiel Stork, Johannes Petrus Maria Tommassen, Vincent Weynants
  • OUTER MEMBRANE VESICLES AND USES THEREOF
    Publication number: 20100047287
    Abstract: The present invention discloses a Gram negative bacterium in which the expression of a protein involved in LPS transport to the outer membrane is functionally down-regulated such that the level of LPS in the outer membrane is decreased compared to a wild-type Gram negative bacterium. Down regulation of Imp and MsbA proteins can result in such a bacterium. Outer membrane vesicle preparations derived from the Gram negative bacterium of the invention can be used in vaccines to provide protection against bacterial infection.
    Type: Application
    Filed: November 3, 2009
    Publication date: February 25, 2010
    Applicants: GLAXOSMITHKLINE S.A., UTRECHT UNIVERSITY
    Inventors: Martine Petronella Bos, Jan Poolman, Boris Tefsen, Johannes Petrus Maria Tommassen
  • Outer membrane vesicles and uses thereof
    Patent number: 7628995
    Abstract: The present invention discloses a Gram negative bacterium in which the expression of a protein involved in LPS transport to the outer membrane is functionally downregulated such that the level of LPS in the outer membrane is decreased compared to a wild-type Gram negative bacterium. Down regulation of Imp and MsbA proteins can result in such a bacterium. Outer membrane vesicle preparations derived from the Gram negative bacterium of the invention can be used in vaccines to provide protection against bacterial infection.
    Type: Grant
    Filed: December 21, 2004
    Date of Patent: December 8, 2009
    Assignees: GlaxoSmithKline Biologicals S.A., University of Utrecht
    Inventors: Martine Petronella Bos, Jan Poolman, Boris Tefsen, Johannes Petrus Maria Tommassen